11-02/03 :: February / March 2011
nanotimes
Companies Facts
quarter. The products are derived from non-decene alpha olefin feedstocks and based on proprietary Chevron Phillips Chemical metallocene technology.
http://www.cpchem.com
C
ritical Pharmaceuticals announced the results of a long-term preclinical study that confirms the
excellent local tolerability of its unique and propri- etary CriticalSorb™ nasal drug delivery technology. The emerging biotechnology company is now pre- paring to take the technology forward into a phase I clinical trial. CriticalSorb™ is already used in a number of marketed drugs for intravenous and oral administration and the results of this study complete the toxicology package for the nasal route of admi- nistration. CriticalSorb™ is a best in class absorption promoter that enables the nasal delivery of biologi- cal and challenging small molecule drugs. Biological drugs represent a $90 billion market, and yet nearly all need to be administered by frequent injection. CriticalSorb™ has the potential to transform the delivery of biological drugs by enabling non-invasive delivery that would be strongly preferred by patients.
http://www.criticalpharmaceuticals.com
C
VD Equipment Corporation (NASDAQ: CVV) received new orders during January, 2011. The
orders totaled approximately $9.3 million. These or- ders are for both production and research equipment in the fields of Solar, LED’s and Nanotechnology.
CVD Equipment Corporation and Graphene Labo- ratories Inc. now offer commercial CVDGraphene™ research starter materials and customization services for transparent and conductive CVD grown Gra- phene films.
Furthermore, CVD Equipment Corporation an- nounced a seventh consecutive profitable year. On revenue of approximately $5,123,000 for the three months ended December 31, 2010 we achieved net earnings of $375,000 or $0.08 per basic and diluted share and on revenue of approximately $16,258,000 for fiscal year ended December 31, 2010 we achie- ved net earnings of $532,000 or $0.11 per basic and diluted share. Revenue for fiscal year ended Decem- ber 31, 2010 increased due to increasing demand for energy saving and energy generation materials and products needed to address rising energy costs. Gross profit margin for Q4, 2010 was 41.6%, raising the overall gross profit margin for fiscal year ended December 31, 2010 to 36.2%. This was accomplis- hed through a combination of greater efficiencies in purchasing and labor on an increase in revenue, a trend we expect to continue.
http://www.graphene-supermarket.com http://www.cvdequipment.com
T
he Dow Chemical Company (NYSE: DOW) and RUSNANO have signed a memorandum of
understanding to evaluate potential cooperation in fast-growing areas such as energy efficiency, infra- structure, light-weight materials, and life sciences.
Through this agreement, both companies will eva- luate and define potential joint venture projects to pursue collaborative investments in Russia. The parties have also agreed to exchange technical and commercial information on up-and-coming activities. “Our goal is to develop commercially-meaningful joint projects that help to address key issues in Russia, and leverage Dow technology to support job creation and economic development,” stated Heinz Haller, Executive Vice President and Chief Commer-
25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95